Eleven women with hyperprolactinemic amenorrhea were treated with a combined estrogen/progestogen preparation (Loestrin 30) for 3 months as hormone replacement therapy because of estrogen deficiency, with a view to protection against osteoporosis. Serum prolactin levels rose during the 1st month of treatment (p < 0.05) but did not rise significantly further during the 2nd and 3rd months. The levels rose in proportion to pretreatment levels by 28% (median), and fell significantly but not completely during the 1-week treatment-free intervals. After the study period, prolactin values appeared to remain stable in those women who continued longer on treatment, and returned to around pretreatment values in those who stopped. In one woman there was radiological evidence of pituitary tumor growth during treatment. This study shows that estrogen/progestogen treatment in standard contraceptive dosage usually leads to only moderate and non-progressive stimulation of pituitary activity in women with hyperprolactinemic amenorrhea, but occasional excessive growth of a prolactinoma can occur and treatment needs to be monitored. Women with relatively high prolactin levels seem to be at particular risk. Safer variations of estrogen therapy such as lower dosage or combination with a protective low dose of a dopamine agonist should also be considered.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/09513599209015553 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Are prolactin levels efficient in predicting a pituitary lesion in patients with hyperprolactinemia?
Endocrine
May 2024
Division of Endocrinology, Diabetology and Metabolism; Department of Medical Sciences, University of Turin, Turin, Italy.
Article Synopsis
- The study aimed to assess the relationship between prolactin (PRL) levels and pituitary abnormalities in a diverse group of patients with hyperprolactinemia, as existing guidelines primarily focus on women.
- Researchers analyzed data from 1,253 patients, identifying 139 who met criteria for inclusion; findings revealed that 76.3% had pituitary disease, with PRL levels showing limited effectiveness in predicting abnormalities, particularly when high PRL values were excluded.
- The conclusion highlights a significant occurrence of pituitary issues in hyperPRL patients, suggesting that MRI scans are essential for diagnosis, emphasizing the need for further research to clarify PRL thresholds for imaging.
Effects of long-term proton pump inhibitor use on sexual hormones and sexual and reproductive health in female patients.
Endocrine
February 2024
Department of Pharmacy, COMSATS University Islamabad, Abbottabad Campus, Abbottabad, Pakistan.
Purpose: Proton pump inhibitors (PPIs) are widely used to treat a range of gastrointestinal diseases around the world. Long-term use of PPIs has been associated to a variety of undesirable effects. Although short-term therapy has been shown to have little or no effect on endocrine hormone in women, however, its long-term safety has received little attention.
View Article and Find Full Text PDFRopinirole for the Treatment of Hyperprolactinemia: A Dose-Escalation Study of Efficacy and Tolerability.
J Clin Endocrinol Metab
January 2024
Department of Medicine, Columbia University, Vagelos College of P&S, New York, NY 10032, USA.
Context: Treatment of hyperprolactinemia with ergoline dopamine agonists (DAs) can be complicated by intolerance and resistance.
Objective: This study examines the efficacy and tolerability of the nonergot DA ropinirole for the long-term treatment of hyperprolactinemia.
Methods: Twelve hyperprolactinemic women were treated with ropinirole in a 6-month, open-label, dose-escalation trial; 7 of the 12 continued treatment in an extension study for up to 17 months.
Cardiometabolic Effects of Cabergoline and Combined Oral Contraceptive Pills in Young Women with Hyperprolactinemia: A Pilot Study.
J Clin Med
April 2023
Department of Internal Medicine and Clinical Pharmacology, Medical University of Silesia, Medyków 18, 40-752 Katowice, Poland.
Although dopaminergic agents are the drugs of choice in treatment of prolactin excess, women who cannot be treated with these agents are recommended to receive estrogen preparations. The aim of this study was to compare cardiometabolic effects of both treatment options. The study population included three groups of young women.
View Article and Find Full Text PDFWhat is the optimal prolactin cutoff for predicting the presence of a pituitary adenoma in patients with polycystic ovary syndrome?
Int J Med Sci
April 2023
Department of Neurosurgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Hyperprolactinemia (HPRL) and polycystic ovary syndrome (PCOS) are common causes of infertility in women of reproductive age. A pituitary adenoma (PA) is the most common type of brain tumor that causes HPRL. In the neurosurgical field, the co-existence of PA and PCOS is not common.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!